Case # | Gender | Age | Hemoglobinopaty | Year of HCV diagnosis | HCV genotype | HCV-RNA (IU/l) | Hemoglobin (g/dl) | ALT (IU/l) | Metavir score | HCV therapy | Duration of therapy (weeks) | Response | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | F | 35 | Thalassemia mayor | 1990 | 2a | Baseline | 3,590,000 | Baseline | 10.1 | Baseline | 112 | F2 (estimated through liver elastography) | Peg-Interferon 100 µg per week | 24 | Responder |
Week 4 | nd | Week 4 | Week 4 | 61 | |||||||||||
Week 12 | nd | Week 12 | Week 12 | 53 | |||||||||||
Week 24 | nd | Week 24 | Week 24 | Normal | Ribavirin 800 mg/day | ||||||||||
End of treatment | nd | End of treatment | End of treatment | Normal | |||||||||||
Follow up | nd | Follow up | Follow up | Normal | |||||||||||
4 | M | 38 | Thalassemia mayor | 1991 | 4 | Baseline | 18,900,000 | Baseline | 8.9 | Baseline | F2 (estimated through liver elastography) | Peg-Interferon 180 µg per week | 24 | Non responder | |
Week 4 | 3810 | Week 4 | Week 4 | ||||||||||||
Week 12 | 3830 | Week 12 | Week 12 | ||||||||||||
Week 24 | 21,900 | Week 24 | Week 24 | Ribavirin 800 mg/day | |||||||||||
End of treatment | 21,900 | End of treatment | End of treatment | ||||||||||||
Follow up | 3,350,000 | Follow up | Follow up | ||||||||||||
5 | M | 31 | Drepanocytosis | 1990 | 1b | Baseline | 745,000 | Baseline | 8.3 | Baseline | Twofold the normal | F2 | Peg-Interferon 100 µg per week | 72 | Responder |
Week 4 | not available | Week 4 | Week 4 | ||||||||||||
Week 12 | 34470 | Week 12 | Week 12 | ||||||||||||
Week 24 | nd | Week 24 | Week 24 | Ribavirin 800 mg/day | |||||||||||
End of treatment | nd | End of treatment | End of treatment | ||||||||||||
Follow up | nd | Follow up | Follow up | ||||||||||||
6 | F | 42 | Thalassemia mayor | 1991 | 2a | Baseline | 3,430,000 | Baseline | 8.9 | Baseline | 106 | F2 (estimated through liver elastography) | Peg-Interferon 100 µg per week | 24 | Relapser |
Week 4 | nd | Week 4 | Week 4 | ||||||||||||
Week 12 | nd | Week 12 | Week 12 | ||||||||||||
Week 24 | nd | Week 24 | Week 24 | Ribavirin 800 mg/day | |||||||||||
End of treatment | nd | End of treatment | End of treatment | ||||||||||||
Follow up | 1,360,000 | Follow up | Follow up |